Brand and Other Names:Zemplar
- Classes: Vitamin D Analogs
Dosing & Uses
Dosage Forms & Strengths
Prevention & Treatment of Secondary Hyperparathyroidism
Associated with Chronic Kidney Disease (Stage 5)
Associated with Chronic Kidney Disease (Stage 3 & 4)
- PTH ≤500 pg/mL: 1 mcg PO qDay OR 2 mcg PO 3 times/week
- PTH >500 pg/mL: 2 mcg PO qDay OR 4 mcg PO 3 times/week
- Do not administer 3 times/week dosing no more frequently than every other day
- Titrate dose based on response
Serum PTH, calcium & phosphorus
Monitoring parameters (Stage 5)
- PTH same or increased: Increase dose
- PTH level decreased by <30%: Increased dose
- PTH level decreased by >30% & <60%: Maintain dose
- PTH level decreased by >60%: Decrease dose
- PTH level 1.5-3 times upper limit of normal: Maintain dose
Monitoring parameters (Stage 3 & 4)
- Serum PTH at 2-4 week intervals
- PTH same or increased: Increase by 1 mcg/day OR 2 mcg three times/week
- PTH decreased <30%: Increase by 1 mcg/day OR 2 mcg three times/week
- PTH decreased >30% or <60%: Maintain current dose
- PTH decreased >60%: Decrease 1 mcg/day OR 2 mcg three times/week
- PTH <60 pg/mL: Decrease 1 mcg/day OR 2 mcg three times/week
Dosage Forms & Strengths
Prevention & Treament of Secondary Hyperparathyroidism
Serum PTH, calcium & phosphorus
Monitoring paremeter (Stage 5)
- Same or Increasing PTH level: Increase dose
- PTH level decreased <30%: Increase dose
- PTH level decreased > 30% & < 60%: Maintain current dose
- PTH level decreased > 60%: Decrease dose
- PTH level 1.5-3 times upper limit of normal: Maintain current dose
Serious - Use Alternative
Significant - Monitor Closely
Increase in blood creatinine
Hypercalcemia, hypervitaminosis D
Monitor serum calcium, serum phosphorus, and serum or plasma iPTH during initial dosing or following any dose adjustment; in pre-dialysis patients, paricalcitol capsules may increase serum creatinine and therefore decrease the estimated GFR (eGFR)
Monitor serum calcium and phosphorus frequently; reduce dose or stop the drug if calcium (in mg/dL) times phosphorus (in mg/dL) product >75
Excessive administration of paricalcitol Capsules can cause over suppression of PTH, hypercalcemia, hypercalciuria, hyperphosphatemia, and adynamic bone disease; prescription-based doses of vitamin D and its derivatives should be withheld during pericalcitol therapy
Avoid excessive use of aluminum containing compounds
Patients receiving digitalis; digitalis toxicity is potentiated by hypercalcemia
Strong CYP3A4 inhibitors may increase paricalcitol AUC
Injection solution doesn't contain preservatives; discard unused portions
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if distributed into breast milk, use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Synthetic vitamin D analog, reduces parathyroid hormone (PTH)
Bioavailability (PO): 72%
Protein Bound: 99.8%
Vd: 44-46 L in CRF; healthy patients 34 L
Extensively metabolized in liver
At least 5 unknown metabolites
Half-Life: 14-20 hr in ESRD
Total Body Clearance: 2.5-4 L/hr
Excretion: Feces 74%; urine 16%
Hemodialysis: Not dialyzable
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs